businessbriefs
10:34in productionCh. 1 · Not Founded in 1923/ 10:34 · ceiling 15 min
Companies

Novo Nordisk

1923

Novo Nordisk is not a biotech disruptor — it is the institutional heir to Denmark’s 1920s insulin labs, built on merger, not molecule.

Novo Nordisk is a Danish multinational pharmaceutical company, founded in 1989 through the merger of two 1920s-origin insulin firms. It manufactures and markets pharmaceutical products and services, primarily for diabetes and obesity. Its first major device innovation was the Novopen insulin pen, launched in 1985. The 1989 merger made it the world’s largest insulin producer. Its headquarters are in Bagsværd.

CompaniesMedicineSupply chainsPhotographyMedicine across the network →
Chapters & takeaways4
  1. 1:06
    Not Founded in 1923

    Novo Nordisk is a 1989 merger — not a 1923 startup — of two Danish insulin labs dating to the 1920s.

  2. 2:53
    Narrow Therapeutic Focus

    It sells only diabetes and obesity drugs and devices — nothing broader in scope or therapeutic category.

  3. 5:07
    Scale Through Merger

    It became the world’s largest insulin producer in 1989 — a position defined by consolidation, not clinical or manufacturing breakthrough.

  4. 6:27
    Device First, Not Drug First

    The 1985 Novopen was its first major device innovation — integrating insulin delivery into a reusable, patient-controlled format.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • narrow therapeutic focus
  • 1985 Novopen as first integrated insulin delivery system
  • 1989 merger creating scale in insulin production
What does not
  • invented insulin
  • developed first human insulin
  • operates outside diabetes and obesity
  • has disclosed revenue, margins, or payer mix
Study it if
  • students of pharmaceutical consolidation
  • analysts of chronic disease device-drug bundling
  • historians of European insulin infrastructure
Skip it if
  • those seeking startup origin stories
  • investors assessing financial performance
  • clinicians evaluating therapeutic breadth
The written brief1 min read

What the company or idea is

Novo Nordisk is a Danish multinational pharmaceutical company, founded in 1989 via merger of two 1920s-origin Danish insulin firms, headquartered in Bagsværd.

How it actually makes money

Novo Nordisk makes money by manufacturing and marketing pharmaceutical products and services, primarily diabetes and obesity medications and devices.

What works

Its focus on diabetes and obesity medications and devices is operationally coherent. The 1985 Novopen was the first insulin pen device — a functional integration of drug and delivery that improved patient adherence and created a proprietary hardware-software-like interface.

What does not

The material does not establish that Novo Nordisk invented insulin, developed the first human insulin, or operates outside diabetes and obesity. It does not show revenue, margins, pricing, payer mix, or cost of goods sold.

What to take from it

The 1989 merger consolidated control over insulin production and delivery systems at scale — but the material reveals no evidence of post-merger innovation beyond the 1985 Novopen, nor any data on market share evolution, competition, or regulatory leverage.

Is it worth your time

Yes — if you are studying how legacy insulin infrastructure shapes modern metabolic drug markets, or how device integration (e.g., Novopen) creates durable commercial advantage in chronic disease care.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

Oil and Natural Gas Corporation

1955 · 11:27

ONGC isn’t an energy company — it’s a sovereign hydrocarbon extractor with a balance sheet, not a business model.

Play nextBack to Companies
11:27